argenx SE (NASDAQ:ARGX) Stock Holdings Lifted by Bank of Montreal Can

Bank of Montreal Can boosted its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 11.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,236 shares of the company's stock after acquiring an additional 929 shares during the quarter. Bank of Montreal Can's holdings in argenx were worth $5,680,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its holdings in argenx by 28.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company's stock valued at $1,875,000 after buying an additional 768 shares in the last quarter. Captrust Financial Advisors acquired a new stake in shares of argenx in the 3rd quarter worth approximately $243,000. Stifel Financial Corp increased its stake in argenx by 15.3% in the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock valued at $4,788,000 after purchasing an additional 1,170 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in argenx by 17.5% during the third quarter. Sanctuary Advisors LLC now owns 2,064 shares of the company's stock worth $1,119,000 after purchasing an additional 308 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of argenx during the third quarter valued at $652,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on ARGX shares. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Piper Sandler lifted their target price on shares of argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 7th. Oppenheimer increased their price target on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Guggenheim raised their price objective on argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Finally, William Blair reiterated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $699.28.

argenx Stock Performance

Shares of ARGX stock traded up $8.61 on Friday, hitting $596.20. The stock had a trading volume of 321,813 shares, compared to its average volume of 309,060. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21. The firm has a market capitalization of $36.23 billion, a price-to-earnings ratio of -677.50 and a beta of 0.60. The stock's 50 day moving average is $602.53 and its 200-day moving average is $605.54.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Equities analysts expect that argenx SE will post 3.13 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.